文献速递皮肤肿瘤

探索全局cfDNA片段组学作为黑色素瘤真实世界患者生物标志物

Exploring global cfDNA fragmentomics as a biomarker in real-world patients with melanoma.
PubMed 文献 · J Invest Dermatol · 2026-02-06

本研究对235例AJCC II-IV期黑色素瘤患者(549份血浆样本)和11名表型高危健康对照进行纵向前瞻性研究,通过常规毛细管电泳量化6个片段大小范围。活动性疾病样本显示短片段(20-150 bp)和短二核小体片段(250-320 bp)富集及异质性增加,单核小体片段(160-180 bp)耗竭;对活动性疾病与无病样本的区分能力中等(AUC最高0.64),与血清S100(AUC 0.68)相当,高于乳酸脱氢酶(AUC 0.60)。在切除患者中,250-320 bp变异性和短片段比率可预测无复发生存和无远处转移生存(每增加1 SD的HR约1.5-2.4),在约3-6个月时性能最强。

要点

  • cfDNA片段组学可捕捉黑色素瘤活动性疾病相关的片段化改变。
  • 短片段和短二核小体片段富集、单核小体片段耗竭提示肿瘤相关核酸酶/染色质加工。
  • 片段组学指标对切除患者有短期预后价值,与S100/LDH相关性弱,提供独立信息。

核心结论

  • 低成本电泳为基础的cfDNA片段组学可捕捉黑色素瘤有临床意义的片段化改变,并提供补充性短期预后信息。

研究设计与样本

  • 纵向前瞻性研究,纳入235例AJCC II-IV期黑色素瘤患者(549份血浆样本)和11名表型高危健康对照,通过常规毛细管电泳量化6个片段大小范围。

主要发现

  • 活动性疾病样本显示短片段(20-150 bp)和短二核小体片段(250-320 bp)富集及异质性增加,单核小体片段(160-180 bp)耗竭。
  • 活动性疾病与无病样本的区分AUC最高0.64,与血清S100(AUC 0.68)相当,高于乳酸脱氢酶(AUC 0.60)。
  • 在切除患者中,250-320 bp变异性和短片段比率预测无复发生存和无远处转移生存,每增加1 SD的HR约1.5-2.4,约3-6个月时性能最强。
  • 片段组学指标与S100/乳酸脱氢酶相关性弱,支持独立生物学信息。

临床怎么用

  • cfDNA片段组学可作为黑色素瘤风险适应随访的补充工具,支持整合入更高分辨率或多模式cfDNA检测。

局限性

  • 区分活动性疾病与无病样本的效能中等(AUC最高0.64)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Circulating cell-free DNA fragmentomics-the analysis of cell-free DNA fragment-length profiles-has been explored as a biomarker across cancers, but evidence in melanoma is limited. We conducted a longitudinal prospective study of 235 patients with American Joint Committee on Cancer stages II-IV melanoma (549 plasma samples) and 11 phenotypic high-risk healthy controls, quantifying 6 fragment-size ranges by routine capillary electrophoresis. Linear mixed-effects modeling and receiver operating characteristic analyses evaluated associations with disease status; time-dependent receiver operating characteristic and mixed-effects Cox regression assessed prognostic value in resected patients. Active-disease samples showed a fragmentation shift: enrichment and increased heterogeneity of short (20-150 bp) and short-dinucleosome (250-320 bp) fragments, with depletion of mononucleosome fragments (160-180 bp), consistent with tumor-associated nuclease/chromatin processing. Discrimination of active disease versus disease-free samples was modest (area under the curve up to 0.64), comparable with serum S100 (area under the curve 0.68) and higher than lactate dehydrogenase (area under the curve 0.60). In resected patients, 250-320 bp variability and short-fragment ratios predicted relapse-free and distant-metastasis-free survival from blood draw (hazard ratio ≈ 1.5-2.4 per 1 SD increase) after clinical adjustment, with strongest performance over ∼3-6 months. Correlations with S100/lactate dehydrogenase were weak, supporting independent biological information. Low-cost electrophoresis-based fragmentomics captures clinically meaningful shifts and provides complementary short-term prognostic information, supporting integration into higher-resolution or multimodal cell-free DNA assays for risk-adapted follow-up.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Rizo-Potau D, Forniés-Mariné A, Villanueva-Cañas JL, et al. Exploring global cfDNA fragmentomics as a biomarker in real-world patients with melanoma. J Invest Dermatol. 2026. PMID: 41655951. doi:10.1016/j.jid.2026.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。